UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M

May 10, 2022 9:10 AM ETUroGen Pharma Ltd. (URGN)By: Pranav Ghumatkar, SA News Editor
  • UroGen Pharma press release (NASDAQ:URGN): Q1 GAAP EPS of -$1.25 beats by $0.09.
  • Revenue of $13.56M (+81.0% Y/Y) misses by $1.62M.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.